Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2025-04-14 Proxy Solicitation & In…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC for the 2025 Annual Meeting of Stockholders of Sutro Biopharma, Inc. It includes detailed information about the solicitation of proxies, voting procedures, proposals to be voted on (such as election of directors, ratification of auditors, executive compensation advisory vote, and a reverse stock split amendment), and corporate governance matters. The document is not an announcement or a brief notice but a full proxy statement intended to inform shareholders prior to the annual meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI). It is not an Annual Report (10-K), Earnings Release, or other report type. The length and content confirm it is a full proxy statement, not just a notice or announcement. Therefore, the correct classification is PSI with high confidence.
2025-04-14 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 10, 2025, reporting the departure of a board member, John Freund, M.D., who will not stand for re-election at the upcoming Annual Meeting. The key content is about a change in the company's board of directors. There are no financial statements or detailed financial data, nor is this an announcement of a report publication. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2025-04-14 English
Director's Dealing 2025
Director's Dealing
2025-04-08 English
Director's Dealing 2025
Director's Dealing
2025-04-08 English
Director's Dealing 2025
Director's Dealing
2025-04-08 English
Director's Dealing 2025
Director's Dealing
2025-04-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.